Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses

Reuters03-27

Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses

Overview

Israel healthcare and energy tech firm's 2025 net loss narrowed sharply from prior year
Company completed DeepSolar and LayerBio acquisitions, expanding into solar analytics and ocular drug delivery
R&D expenses fell sharply due to lower clinical trial costs, general expenses remained stable

Result Drivers

ACQUISITIONS - Expansion into solar analytics and ocular drug delivery through DeepSolar and LayerBio acquisitions drove business transformation
R&D EXPENSES - Lower clinical trial costs reduced R&D expenses, partially offset by new LayerBio activities
COMMERCIAL PROGRESS - DeepSolar advanced from acquisition to early commercial deployment with new customer agreements and product launches

Company press release: ID:nGNX3kJSvr

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY Net Income		-$4.80 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622826067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622826067","market":"fut","top_or_hot":-1,"title":"Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&amp;D expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Israel healthcare and energy tech firm's 2025 net loss narrowed sharply from prior year</p></li><li><p>Company completed DeepSolar and LayerBio acquisitions, expanding into solar analytics and ocular drug delivery</p></li><li><p>R&amp;D expenses fell sharply due to lower clinical trial costs, general expenses remained stable</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITIONS - Expansion into solar analytics and ocular drug delivery through DeepSolar and LayerBio acquisitions drove business transformation</p></li><li><p>R&amp;D EXPENSES - Lower clinical trial costs reduced R&amp;D expenses, partially offset by new LayerBio activities</p></li><li><p>COMMERCIAL PROGRESS - DeepSolar advanced from acquisition to early commercial deployment with new customer agreements and product launches</p></li></ul><p>Company press release: <span>ID:nGNX3kJSvr</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-$4.80 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsraeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&amp;D expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Israel healthcare and energy tech firm's 2025 net loss narrowed sharply from prior year</p></li><li><p>Company completed DeepSolar and LayerBio acquisitions, expanding into solar analytics and ocular drug delivery</p></li><li><p>R&amp;D expenses fell sharply due to lower clinical trial costs, general expenses remained stable</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITIONS - Expansion into solar analytics and ocular drug delivery through DeepSolar and LayerBio acquisitions drove business transformation</p></li><li><p>R&amp;D EXPENSES - Lower clinical trial costs reduced R&amp;D expenses, partially offset by new LayerBio activities</p></li><li><p>COMMERCIAL PROGRESS - DeepSolar advanced from acquisition to early commercial deployment with new customer agreements and product launches</p></li></ul><p>Company press release: <span>ID:nGNX3kJSvr</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-$4.80 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRFX","symbol_name":"PRF Technologies Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL1N40F0DY:1","article_id":"2622826067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622826067","pubTimestamp":1774613359,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expensesOverviewIsrael healthcare and energy tech firm's 2025 net loss narrowed sharply from prior yearCompany completed De","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRFX":"PRF Technologies Ltd.","BK4007":"制药"},"translate_title":"以色列药物输送公司PainReform 2025年净亏损因研发费用减少而收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRFX":0.9},"content_text":"Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expensesOverviewIsrael healthcare and energy tech firm's 2025 net loss narrowed sharply from prior yearCompany completed DeepSolar and LayerBio acquisitions, expanding into solar analytics and ocular drug deliveryR&D expenses fell sharply due to lower clinical trial costs, general expenses remained stableResult DriversACQUISITIONS - Expansion into solar analytics and ocular drug delivery through DeepSolar and LayerBio acquisitions drove business transformationR&D EXPENSES - Lower clinical trial costs reduced R&D expenses, partially offset by new LayerBio activitiesCOMMERCIAL PROGRESS - DeepSolar advanced from acquisition to early commercial deployment with new customer agreements and product launchesCompany press release: ID:nGNX3kJSvrKey DetailsMetricBeat/MissActualConsensus EstimateFY Net Income-$4.80 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622826067","isCrawlerRequest":true}